2 results
Approved WMOCompleted
To evaluate the effect of MEDI6012 on infarct size compared with placebo.
Approved WMORecruiting
Primary Objective: Safety Run-in Period:To evaluate the occurrence of tumor lysis syndrome (TLS) and doselimiting toxicities (DLTs) with the concurrent administration of ibrutinib and venetoclax.Randomization Phase:To evaluate whether theā¦